Haemonetics (HAE) Presents at the Morgan Stanley 20th Annual Global Healthcare Conference - Slideshow

Financial Performance & Growth - Haemonetics reported FY'22 revenue of $351 million for Plasma, $299 million for Blood Center, and $323 million for Hospital business units[7] - The company experienced a 14% GAAP revenue growth in FY'22, with organic revenue growth at 7%[44] - Haemonetics is targeting mid-teens CAGR in adjusted diluted EPS[46] Market & Strategy - The source plasma market has a FY'20 Total Addressable Market (TAM) of approximately $800 million and is growing at 8-10%[13] - The plasma-derived therapies market has a FY'20 TAM of approximately $27 billion, with Immunoglobulins accounting for 55%[14] - Haemonetics aims to compete in winning segments and geographies to achieve leading positions, focusing on revenue, profitability, and cash flow growth[10] Operational Excellence - The Operational Excellence Program is projected to yield gross savings of $115 million - $125 million from FY'20 through FY'25[39] - The Operational Excellence Program is expected to achieve approximately 30% net savings[39]